Rajendra Prasad, PhD, Assistant Professor, School of Biochemical Engineering, IIT (BHU), Varanasi
Rajendra Prasad | PhD, Assistant Professor, School of Biochemical Engineering, IIT (BHU), Varanasi
Rajendra Prasad,PhD, Assistant Professor, School of Biochemical Engineering, IIT (BHU), Varanasi
Biography
Rajendra Prasad is an Assistant Professor at the School of Biochemical Engineering, IIT (BHU) Varanasi, India. He is leading the Bright-NanoGhost group for early-stage CANCER diagnosis and therapeutics. Rajendra has completed postdoctoral training at Tufts University, USA; Technion-Israel Institute of Technology, Israel; NOVA Medical School, Portugal; and IIT Bombay, India. Rajendra obtained a PhD degree from CSIR-NCL, Pune, India.
He has published high impact top tier journals like Signal Transduction and Targeted Therapy (Nature, IF 80.1), ACS Nano (ACS, IF 16.0), Nano Letters (ACS, IF 9.1), Matter (Cell Press, IF 17.5), Journal of Controlled Release (Elsevier, IF 11.4), Adv. Funct. Mater. (Wiley, IF 19.9), Bioconjugate Chemistry (ACS, IF 3.9), Adv. Healthcare Mater. (Wiley, IF 11), etc. Rajendra holds more than 30 National and International Patents (more than 18 are granted/or published), 8 trademarks and 2 Edited Books. Rajendra has received multiple prestigious fellowships such as PBC, JSPS, IPDF, SAAS and holds membership in the World Molecular Imaging Society, American Association for Cancer Research, and Royal Society of Chemistry. His recent publication with pioneers of the nanomedicine field, such as Bob Langer, Dan Peer, João Conde, Twan Lammers and Teri Odom has received huge attention.
Rajendra is also serving as an Associate Editor at Nanotheranostics (IVYSPRING), Early Career Advisory Board Member at Nano Letters (ACS), Editorial Board Member at npj Imaging (Published by Nature) and Guest Editor at Nanoscale (RSC).
Interview
NanoSphere: Tell us a bit about yourself—your background, journey, and what led you to where you are today.
Rejendra: I think the biggest potential of molecular imaging is identifying disease at an early stage by sending molecular or nanoprobes to the targeted site. This approach can tell us what is actually happening within the disease site by providing the molecular changes/signature. Further, we can see where the imaging agents/probes are going, how much of them are reaching to the disease site, and potentially how the cancer site is responding towards them. So, the molecular signature of the disease site can help us to design better therapeutic platforms and, eventually, choose the right treatment for the right patient. But there is still a gap between what we can demonstrate in the laboratory and what we can realistically do in patients. In reality, the disease site is much more complex and challenging than the model we design.
Therefore, imaging or therapeutic platforms (known as nanomedicines) that perform very well in a cell culture or animal model may behave very differently in humans. Moreover, there are issues of safety, reproducibility, large-scale manufacturing, batch-to-batch variability, etc. So, I believe we need to take a dual approach-engineering clinically relevant nanomedicines while simultaneously gaining a deeper understanding of the disease microenvironment that ultimately governs their performance and therapeutic efficacy. Solving these issues can help us understand the whole journey of a nanomedicine and make the approach more precise and, hopefully, more useful in clinical studies and practice.
Rejendra's references
- https://brightnanog.com
- https://pubs.acs.org/nalefd/pages/Editorial_Board
- https://www.ntno.org/editorial
- https://scholar.google.com/citations?user=X0kiDpAAAAAJ&hl=en
- Rajendra-Voices of Nanomedicine: Blueprint Guidelines for Collaboration in Addressing Global Unmet Medical Needs, ACS Nano (2025) 19 (3): 2979–2991

